Earnings Call · Q4 FY2022·2023-03-27

Q4 22EPS -79.17%·Rev n/aQ3 22EPS -6.06%·Rev n/aQ2 22EPS +7.50%·Rev n/aQ1 22EPS -2.78%·Rev n/a⚠ consensus missing

CytomX Therapeutics, Inc. CTMX

Chris Ogden — Chief Financial Officer

Sean McCarthy — Chief Executive Officer

−15.1%1d on move date−14.9% vs SPY3d−17.3%5d−14.0%

Research tier

Behavioral profile computed for 2 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more CTMX calls or request research access.

More CTMX calls Browse calls Request research access